January 2025 – Kinstellar Budapest, acting as the lead counsel for Hungary, has successfully closed the landmark Project Bluesky transaction, advising the Hungarian Power Exchange (HUPX) and the Hungarian Transmission System Operator, MAVIR.

December 2024 – The Antimonopoly Committee of Ukraine (AMC) is increasing enforcement efforts against so-called “gun-jumping” violations (i.e. a merger or acquisition executed without the prior approval of the AMC), demanding stricter scrutiny even...

December 2024 – The Turkish Competition Authority (“TCA”) announced on 3 December 2024 that the much-anticipated Guidelines on Competition Infringements in Labour Markets (“Guidelines”) were been adopted by the Competition Board at its meeting...

December 2024 – Kinstellar is delighted to announce that Sinan Diniz, a highly regarded competition law expert, has joined our associated law firm in Turkey, KST Law, as a Partner.

October 2024 – Kinstellar has acted as Ukrainian legal counsel to Orbico Group on the acquisition of a controlling stake in SAV 92, a leading Ukrainian distributor of branded international and Ukrainian food and non-food products. This multi-stage transaction...

October 2024 – We are pleased to announce Kinstellar’s Competition Law Conference: Cross-Sector Perspectives, taking place on 15 November 2024 at the Hilton Hotel in Belgrade, Serbia. This exclusive event will bring together leading experts to explore...

September 2024 – On 11 September 2024 the Romanian Competition Council’s (“RCC”) Order no. 2436/2024 implementing the Guidelines on informal guidance on novel or unresolved questions arising in individual cases concerning the application of Art....

July 2024 – Kinstellar is pleased to announce the successful completion of a new recruitment round, welcoming six lawyers to its growing team in Bucharest. The new additions bolster the local team’s offering in the real estate, banking & finance...

June 2024 – The EU Foreign Subsidies Regulation (“FSR”) started to apply on 12 July 2023 as another instrument in the EU regulatory toolkit aimed at preventing distortions of competition on the EU internal market. In the spotlight of the framework...

May 2024 – In Serbia, most of the exclusivity arrangements between pharma companies need to be, prior to their implementation, individually exempt by the Serbian Competition Authority (“SCA”). Most recently, the SCA issued two decisions in the individual...